DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Dapsone for Acute Ischemia Stroke Study

Information source: Cidat, S.A. de C.V.
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Cerebral Stroke; Cerebrovascular Accident, Acute; Cerebrovascular Stroke; Stroke, Acute; Stroke

Intervention: Dapsone (Drug); Placebo (Drug)

Phase: Phase 2/Phase 3

Status: Recruiting

Sponsored by: Cidat, S.A. de C.V.

Official(s) and/or principal investigator(s):
Juan A. Nader, MD, Principal Investigator, Affiliation: Hospital Medica Sur

Overall contact:
Rosa I Florville, MD, Phone: (52-55) 5171-9005, Email: ines.florville@psicofarma.com.mx


The main purpose of the study is to get information about the safety and efficacy of treatment with Dapsone to prevent the disability after ischemic Stroke, in patients diagnosed with anterior territory brain infarct.

Clinical Details

Official title: Clinical Trial Randomized, Placebo-controlled, Using Dapsone as a Neuroprotector During Acute Ischemia Stroke

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Primary outcome: Shift across the board of National Institute of Health stroke scale (NIHSS) and Modified Rankin Scale (mRS)

Secondary outcome: Barthel index

Detailed description: Cerebrovascular diseases are the third cause of mortality around the world. Seventy-five percent of the cases correspond to ischemic stroke, and the remaining 25 % to hemorrhagic infarct. The social impact of Stroke is high as it is the first cause for disabilities. After Stroke, several mechanisms of secondary damage act to spread the damage to the surrounding tissue. Those mechanisms include: 1) Excitotoxicity after excitatory amino acids' release 2) Overproduction of free radicals 3) Exacerbated inflammatory response and 4) Apoptosis. Many neuroprotective strategies have been tested to cope with the already mentioned damaging processes with poor clinical results. Many clinical trials have failed to provide neuroprotection to patients after acute stroke. Then, the need for safe drugs with clinical efficacy to prevent Stroke disability consequences is highly recognized. Dapsone is safe and relatively free of adverse reactions, we propose a clinical trial to assess the safety and efficacy of using this drug in patients with ischemic brain stroke. Methods: A double-blind, placebo-controlled, randomized clinical trial of dapsone is to be conducted from 2009 to 2010. Three-hundred patients with a CT or MRI documented ischemic stroke in the anterior cerebral territory are to be included. Patients with 4 to 20 points of the National Institute of Health Stroke Scale (NIHSS) will be randomly allocated to receive either a single total dose of 250 mg dapsone or placebo within the first 12 h after stroke. For the follow-up, NIHSS on days 0, 2, 7, 30, 60 and 90, modified Rankin scale (mRS) on days 0, 30, 60 and 90, and Barthel index (BI) at day 90, will be all applied. Adverse reactions will be also recorded. The Primary clinical outcome of the patients will be assessed at 90 days after stroke by obtaining the shift analysis from the baseline levels of the scales mRS and NIHSS. Secondary clinical outcome will be the BI at day 90. An interim analysis of the data will be performed when the study have recruited one-hundred patients. Statistical analysis will be performed with the intention-to-treat approach.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Patients with the clinical diagnosis of an acute cerebrovascular event in in the

anterior cerebral territory, within the last 12 hours who match the MRI or axial CT image.

- Patients with 4 o more points of the National Institute of Health Stroke Scale


- Age older than 18 years, both gender

- Non acute cerebrovascular event previous

- Informed consent signed by patient or relatives

Exclusion Criteria:

- Diagnosed with recurrent diseases like: heart failure; Myocardial Infarction up 8

weeks before; ventrivular arrhythmia diagnosed by ECG; Second-Degree and Third-Degree Atrioventricular Block; or Long QT Syndrome.

- Pregnancy

- Allergic reactions to sulfa medications

- Patients with kidney failure and hepatic insufficiency

- Deficiency of glucose-6-phosphate dehydrogenase diagnosed

Locations and Contacts

Rosa I Florville, MD, Phone: (52-55) 5171-9005, Email: ines.florville@psicofarma.com.mx

El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez, Tlalpan, Mexico City. 14269, Mexico; Recruiting
Jorge L Alvarado, MSc, Phone: (52-55) 5606-3822, Ext: 1060, Email: jorgelaa3@hotmail.com
José A Santos, MD, Principal Investigator
Rubén Martínez, MD, Sub-Investigator
Additional Information

Starting date: July 2009
Last updated: June 14, 2010

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017